Foghorn Therapeutics
FHTX
105 hedge funds and large institutions have $212M invested in Foghorn Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
90% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 21
13% more funds holding
Funds holding: 93 → 105 (+12)
1.66% more ownership
Funds ownership: 74.05% → 75.71% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $226M → $212M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$4.09M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.57M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.96M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.72M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$872K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$983K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$871K |
| 3 |
Jane Street
New York
|
-$716K |
| 4 |
Walleye Capital
New York
|
-$257K |
| 5 |
Barclays
London,
United Kingdom
|
-$240K |
FHTX Hedge Fund Activity: Q1 2026 in Review
105 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2026, worth a combined $212M — down 6.1% from $226M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FHTX positions and 9 closed out — a net gain of 13 holders — while 40 added to existing stakes and 21 trimmed.
The largest buyer was Deerfield Management, adding an estimated $4.09M. The largest seller was Millennium Management, cutting an estimated $983K.
- 105 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2026, up from 93 in Q4 2025.
- Funds reported $212M of Foghorn Therapeutics stock for Q1 2026, down 6.1% quarter-over-quarter.
- 22 funds opened new Foghorn Therapeutics positions in Q1 2026 and 9 closed out, a net change of +13 holders.
- The largest Foghorn Therapeutics buyer in Q1 2026 was Deerfield Management, an estimated $4.09M added.
- The largest Foghorn Therapeutics seller in Q1 2026 was Millennium Management, an estimated $983K sold.
Based on aggregated 13F filings for Q1 2026.